Global search

Find data and evidence

Type at least 2 characters. Use arrow keys to review and Enter to open.

Disease overview

Bacterial

Glanders

鼻疽

Evidence-backed informationEN 5/7 applicable sections · ZH 5/7 applicable sectionsUpdated Sep 3, 2026

Glanders is a contagious zoonotic bacterial infection caused by Burkholderia mallei, primarily affecting equids such as horses, mules, and donkeys, with documented spillover to other domestic animals and humans [1]. The pathogen remains endemic across parts of Africa, Asia, the Middle East, and Central and South America, whereas it has been eliminated from North America, Australia, and most of Europe through systematic animal culling and import quarantines [1]. Human infections are rare outside endemic zones but have occurred following laboratory exposure, and the organism is classified as a category B priority bioweapon candidate due to its aerosol infectivity, multidrug resistance, and the current absence of an approved vaccine [1][2].

Read the full clinical and epidemiological profile6
Definition

Glanders is defined as a zoonotic infectious disease caused by the Gram-negative bacterium Burkholderia mallei, a member of the B. pseudomallei complex within the Burkholderia genus [1][2]. The disease nomenclature originates from historical terms denoting glands, reflecting the characteristic nodular lesions observed during infection, with regional synonyms including Latin malleus, Spanish muermo, German Rotz, and Norwegian snive [1]. Species within this genus exhibit substantial intrinsic antimicrobial resistance driven by modified lipopolysaccharides, restricted porin-mediated drug penetration, efflux pump activity, and β-lactamase expression, which complicates microbiological identification and clinical management [2].

Clinical features

Clinical illness typically follows either an acute or chronic trajectory and presents with nonspecific symptoms that frequently impede rapid diagnosis [1]. The acute variant progresses rapidly through coughing, fever, and infectious nasal discharge before advancing to septicaemia and mortality within days [1]. Conversely, the chronic form involves the gradual development of nasal and subcutaneous nodules that eventually ulcerate, potentially leading to death over several months while survivors may function as asymptomatic carriers [1]. Affected equids similarly develop pulmonary nodules and upper respiratory tract mucosal ulcerations [1].

Epidemiology

The disease maintains endemic circulation in African, Asian, Middle Eastern, and Central and South American regions, where it predominantly infects horses, mules, and donkeys with documented cross-species transmission to companion animals, livestock, and humans [1]. Systematic veterinary monitoring, targeted animal destruction, and strict import quarantines successfully eliminated the pathogen from North America, Australia, and much of Europe [1]. Historical human incidence in non-endemic countries is exceptionally low, with the United States recording its last natural case in 1945 and the United Kingdom reporting none since 1928, aside from isolated laboratory exposures [1].

Transmission

Pathogen entry into humans occurs through direct contact with infected animal tissues and bodily fluids, facilitating inoculation via dermal abrasions, oral or nasal mucosal surfaces, and respiratory inhalation [1]. Primary establishment of infection in reservoir hosts generally results from consuming contaminated feed or drinking water [1]. Because the organism readily crosses species barriers to infect people, it is formally categorized as a zoonotic agent [1].

Prevention

Current preventive strategies rely heavily on historical veterinary protocols, including systematic animal inspection, immediate culling of symptomatic individuals, and stringent quarantine measures governing international livestock trade [1]. There is currently no licensed vaccine available in the United States, a therapeutic gap that has accelerated research efforts given the microorganism's potential for weaponization [1]. Mitigation in high-risk environments therefore depends on rigorous biosafety practices and environmental controls rather than immunization [1].

Coding Register
ICD-10
A24.0-A24.4
ICD-11
1B92
Key Statistics
Total cases
0
Peak month
2012-09
Coverage
1 reporting countries · 2012-09-16 → 2026-08-30

Coverage

Reporting countries and regions

1 location

Monthly patterns over time

Data access

Page dataset index with source links and update metadata.

Rows1,458
Updated2026-09-01
Coverage
Partitions4
Source1 series · 729 observations
Official sourcesAuthority, cadence, notes1
Japan

JP NIID Weekly

Japan

Source
weeklyweb

Japan weekly infectious disease surveillance via NIID/JIHS.

Partitioned public data

Choose a time range and format